Seerlinq
AI-enabled remote monitoring for heart-failure patients using non-invasive, at-home cardiac filling pressure measurement.
Website: https://seerlinq.com/
Cover Block
PUBLIC
| Field | Detail |
|---|---|
| Company | Seerlinq |
| Tagline | AI-enabled remote monitoring for heart-failure patients using non-invasive, at-home cardiac filling pressure measurement [Seerlinq] |
| Headquarters | Trnava, Slovakia [Crunchbase] |
| Founded | 2022 [Crunchbase] |
| Stage | Seed [VCBacked, July 2023] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Eastern Europe |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+), including Allan Böhm, Branislav Bezák, and Nikola Jajcay [Healthcare.digital] |
| Funding label | Seed |
| Total disclosed funding | Approximately $982,000 [VCBacked, July 2023] |
Links
Publicly reported
- Website: https://seerlinq.com/
- LinkedIn: https://sk.linkedin.com/in/allan-b%C3%B6hm-42b75b66
Summary and Signal
PUBLIC Seerlinq is a Slovak medtech company building remote monitoring for heart-failure patients, and it merits attention now because it is pairing a clinically specific workflow with a certified Class IIb device in a category where earlier intervention can materially affect hospitalization risk [EU-Startups, March 2026] [Seerlinq] [JACC: Basic to Translational Science, January 2025]. Founded in 2022 and headquartered in Trnava, the company is still early, but the public record already shows a seed financing announced in July 2023 and a nationwide telemedicine programme in Slovakia by March 2026, which is a faster commercialization path than many pre-reimbursement digital health startups achieve [VCBacked, July 2023] [EU-Startups, March 2026].
The product centers on Seerlinq HeartCore, which EU-Startups described as a certified Class IIb medical device under EU MDR 2017/745, designed to monitor cardiac filling pressures remotely through photoplethysmographic signal analysis; a JACC translational study also describes the measurement protocol and algorithmic approach, giving the story more technical grounding than a typical company-only telehealth claim set [EU-Startups, March 2026] [JACC: Basic to Translational Science, January 2025]. In plain terms, Seerlinq is trying to move a clinically meaningful heart-failure signal into the home using a smartphone app, a blood-pressure monitor, and its own device, with clinicians intervening before deterioration leads to admission [Seerlinq] [EU-Startups, March 2026].
The founding team is relevant to the problem definition, even if the public evidence is uneven on exact role titles. Allan Böhm and Nikola Jajcay are publicly identified as co-founders, and Böhm's profile points to active clinical and academic ties in cardiology, while Jajcay brings the technical side of the stack; Branislav Bezák is also listed as a co-founder in company materials and professional profiles, adding another cardiac specialist to the bench [Healthcare.digital] [NextStep Science Podcast] [LinkedIn, retrieved 2026].
On funding, the clearest confirmed datapoint is roughly $982,000 of disclosed seed capital, with investor names across public databases including Slovak Investment Holding, Vision Ventures, Innovate Slovakia, Peter Komornik, and Igor Fratric, although the round history is not fully reconciled across sources [VCBacked, July 2023] [CB Insights] [Crunchbase]. The business model appears to be hardware plus software, and the commercial claim that matters most is reimbursement: Seerlinq's website says the service is fully covered by health insurance in Slovakia, while later company-linked materials also reference Germany, though that cross-border reimbursement posture still needs independent confirmation at the contract level [Seerlinq] [LinkedIn, retrieved 2026].
Over the next 12 to 18 months, the key items to watch are not generic growth markers but proof that the model travels: evidence of sustained physician adoption beyond the initial Slovak base, cleaner third-party verification of reimbursement and paid deployments in Germany, and continued clinical validation that supports expansion without relying on implant-based monitoring pathways [Seerlinq, November 2026] [Life Science Intelligence, December 2025] [Timspark, April 2026]. The company-reported November 2026 milestone of more than 200 patients and over 50 physicians is directionally encouraging, but it is still company-reported, so the next inflection will be whether Seerlinq can convert technical credibility into independently visible commercial traction [Seerlinq, November 2026].
One source, partially checked -- Mix of independent coverage and company-reported operating metrics; device classification and technical approach are corroborated, while traction and some team and reimbursement claims remain partly company-sourced.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Eastern Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed, total disclosed about $982,000 [VCBacked, July 2023] |
Company Overview
PUBLIC
Seerlinq presents as a young Slovak medtech company built around a specific clinical bottleneck: monitoring heart-failure patients at home before deterioration turns into hospitalization. Public company materials describe the service in plain operational terms, a smartphone, a blood-pressure monitor, and a Seerlinq device used from home, with remote oversight by clinical staff [Seerlinq]. Crunchbase lists the company as founded in 2022 and based in Trnava, Slovakia [Crunchbase].
The public record is still thin, but the chronology that can be verified is reasonably straightforward. Seerlinq appears to have been founded in 2022 [Crunchbase], then surfaced in funding databases with a seed round of about $982,000 announced in July 2023 [Crunchbase]. By November 2026, the company said more than 200 patients had joined its program and that it was working with over 50 physicians across Slovakia, which is best read as a company-reported deployment milestone rather than independently audited scale [Seerlinq, November 2026].
The operating footprint also looks somewhat broader than the registered headquarters alone would suggest. While Crunchbase places Seerlinq in Trnava [Crunchbase], the company website markets the service nationally in Slovakia and describes it as fully covered by health insurance for patients, without a co-payment [Seerlinq]. That combination, early capital, a clinical home-monitoring workflow, and a stated nationwide patient service, points to a company that has moved beyond concept stage, even if the public evidence on legal structure, hospital contracting, and cross-border commercialization remains limited [Seerlinq].
One source, partially checked -- This section relies on Crunchbase and Seerlinq's website/blog, with several material operating claims supported only by company sources.
The Product and the Stack
MIXED Seerlinq is trying to solve a clinically narrow, commercially relevant problem: giving heart-failure patients a way to measure signals associated with worsening status at home, before a hospitalization is required. Public descriptions are directionally consistent on the core workflow, even if many operating details still come from the company itself. Seerlinq describes its service as remote cardiac care for heart-failure patients built around a smartphone app, a blood-pressure monitor, and a proprietary device used at home, with clinicians reviewing incoming measurements and intervening when deterioration is detected [Seerlinq] [EU-Startups, March 2026].
The technical differentiation, as presented publicly, rests on non-invasive measurement of cardiac filling pressure through photoplethysmographic signal analysis rather than an implanted sensor. EU-Startups reported in March 2026 that Seerlinq HeartCore is a certified Class IIb medical device under EU MDR 2017/745 and that the system enables remote monitoring of cardiac filling pressures using PPG signal analysis, with the aim of identifying early deterioration before hospitalization becomes necessary [EU-Startups, March 2026]. A January 2025 paper in JACC: Basic to Translational Science described the measurement protocol as a two-minute standing PPG reading followed by a transition to a recumbent position, and said the Seerlinq algorithm analyzes signal changes to differentiate between normal and elevated filling pressures [JACC: Basic to Translational Science, January 2025].
Seerlinq's commercialization layer appears to be more than a standalone device sale, which matters for reimbursement and adoption. On its homepage, the company says the service is fully covered by health insurance for patients in Slovakia and requires no co-payment, while LinkedIn and company materials have also described reimbursement in Germany, though that cross-border claim remains company-sourced in the evidence set [Seerlinq] [LinkedIn, retrieved 2026]. The careers page suggests an in-house product and data buildout, with openings for AI Engineer, Data Scientist, and Backend Developer, which supports a software-plus-device operating model, though any deeper stack description would be speculative (inferred from job postings) [Seerlinq].
One source, partially checked -- Core device classification and PPG-based monitoring are corroborated by EU-Startups and JACC: Basic to Translational Science, while reimbursement geography and several workflow details remain company-sourced.
The Market They Are Entering
PUBLIC
The market matters now because heart-failure management sits at the intersection of two durable pressures, rising chronic-cardiac burden and payer interest in shifting care away from inpatient settings, but the public record on Seerlinq supports the problem statement more clearly than a precise market-size figure [Commonwealth Fund] [EU-Startups, March 2026].
The immediate caution is that no named third-party TAM, SAM, or SOM estimate for Seerlinq’s exact category appears in the supplied source set. That leaves the market definition to be inferred from adjacent public evidence: remote monitoring for heart-failure patients, non-invasive hemodynamic assessment, and reimbursed telemedicine pathways in European care systems [EU-Startups, March 2026] [JACC: Basic to Translational Science, January 2025] [Commonwealth Fund]. In practical terms, Seerlinq is not selling into general wellness or broad consumer wearables. The addressable demand, based on the cited product evidence, is closer to clinically managed heart-failure follow-up where physicians need earlier signal on decompensation risk and where reimbursement can support repeated monitoring outside the hospital [EU-Startups, March 2026] [Seerlinq].
Demand drivers in the public record are more concrete than sizing. Seerlinq’s own service model is built around reducing hospitalization risk through earlier detection of worsening status, and the external evidence aligns with that clinical thesis: EU-Startups describes Seerlinq HeartCore as a Class IIb medical device for remote monitoring of cardiac filling pressures, intended to help clinicians detect deterioration before hospitalization becomes necessary [EU-Startups, March 2026]. The January 2025 JACC: Basic to Translational Science paper also supports the underlying clinical logic by describing a measurement protocol and an algorithm that analyzes photoplethysmography signal changes to distinguish normal from elevated filling pressures [JACC: Basic to Translational Science, January 2025]. That does not establish commercial scale on its own, but it does suggest the company is pointed at a high-cost care pathway where modest improvements in timing can matter economically as well as clinically [JACC: Basic to Translational Science, January 2025] [EU-Startups, March 2026].
Adjacent and substitute markets are easier to identify than direct category boundaries. The closest adjacent market is broader remote patient monitoring for chronic cardiovascular disease, where software, connected peripherals, and clinician workflows are already familiar procurement categories. The substitute set includes implant-based hemodynamic monitoring and standard post-discharge follow-up that relies on symptoms, weight, blood pressure, and periodic visits rather than direct at-home filling-pressure measurement; Timspark framed Seerlinq’s approach as an alternative to implant-based monitoring, which is commercially relevant even if it is not an independent market map [Timspark, April 2026]. That positioning matters because a non-invasive product can widen the practical candidate pool if physicians trust the data and payers support the pathway.
Regulation is not incidental here, it is part of the market structure. EU-Startups reported in March 2026 that Seerlinq HeartCore is certified as a Class IIb device under EU MDR 2017/745, and a secondary regulatory explainer notes that Class IIb devices require certification by a Notified Body before being placed on the EU market [EU-Startups, March 2026] [PatientGuard]. That raises the entry bar relative to wellness monitoring and may help filter the field toward companies with clinical and quality-system depth. Reimbursement is the second structural force. Seerlinq’s homepage states that the service is fully covered by health insurance in Slovakia, without patient co-payment, while LinkedIn-based company materials say reimbursement extends to Slovakia and Germany [Seerlinq] [LinkedIn, retrieved 2026]. The Slovakia claim has direct company support; the Germany claim remains company-linked rather than independently confirmed, so investors should treat cross-border reimbursement breadth as promising but not yet settled [Seerlinq] [LinkedIn, retrieved 2026].
| Market lens | Public evidence | Relevance to Seerlinq |
|---|---|---|
| Heart-failure telemedicine in Slovakia | Company homepage says the service is fully covered by health insurance and provided for heart-failure patients without patient co-payment [Seerlinq] | Supports payer-backed local demand if the reimbursement pathway is durable |
| EU regulated medtech | Seerlinq HeartCore reported as a Class IIb device under EU MDR 2017/745 [EU-Startups, March 2026] | Suggests a regulated market with higher validation and compliance thresholds |
| Clinical monitoring of filling pressure | JACC describes Seerlinq’s protocol and algorithm for distinguishing normal from elevated filling pressures using PPG changes [JACC: Basic to Translational Science, January 2025] | Anchors the company in a clinically specific monitoring niche rather than generic RPM |
| Germany expansion pathway | Company-linked materials state reimbursement in Germany, but independent confirmation is not surfaced in the source set [LinkedIn, retrieved 2026] [Commonwealth Fund] | Points to a larger adjacent market, though public evidence here is still incomplete |
The table shows a market defined less by headline TAM and more by care-pathway fit: reimbursement, regulated-device clearance, and a clinically specific use case are doing most of the work. That generally produces a narrower top-of-funnel than consumer health, but it can also produce stronger defensibility if clinical adoption and payer support hold.
One source, partially checked -- Market context relies on one independent named-publisher source for device status and care model, one academic source for the underlying measurement concept, plus company and LinkedIn materials for reimbursement and expansion claims.
The Competitive Field
MIXED Seerlinq appears to sit in a narrow part of cardiac telemonitoring, where the practical comparison set is less a list of named startup peers from the public record and more a contest between existing heart-failure care pathways, broader remote patient monitoring programs, and invasive hemodynamic monitoring approaches that already have clinical mindshare [EU-Startups, March 2026] [JACC: Basic to Translational Science, January 2025].
The public evidence supports that Seerlinq is building around non-invasive home measurement of cardiac filling pressures for heart-failure patients, delivered through a nationwide telemedicine programme in Slovakia [EU-Startups, March 2026]. That places it against three segments at once. First are incumbent cardiology workflows, where deterioration is often identified through symptoms, office visits, and standard home vitals rather than direct filling-pressure measurement [JACC: Basic to Translational Science, January 2025]. Second are broader remote monitoring offerings that can track patients at home but, based on the evidence here, are not shown to measure left ventricular filling pressures in the same way Seerlinq says it can [PubMed] [EU-Startups, March 2026]. Third are invasive monitoring approaches, which Seerlinq has been publicly framed as trying to displace with a non-invasive alternative rather than compete with on software alone [Timspark, April 2026].
The company has at least one real edge in the public record, but it is narrower than the category language suggests. The strongest verified point is regulatory and clinical specificity: EU-Startups reported in March 2026 that Seerlinq HeartCore is a certified Class IIb medical device under EU MDR 2017/745, and linked the product directly to remote monitoring of cardiac filling pressures using photoplethysmographic analysis [EU-Startups, March 2026]. JACC and PubMed references also indicate that the underlying approach has been described in technical and scientific channels, which matters because it moves the story beyond a generic RPM dashboard and toward a clinically defined measurement problem [JACC: Basic to Translational Science, January 2025] [PubMed]. That edge looks durable if Seerlinq can keep pairing device certification with care-program adoption, but perishable if larger remote monitoring vendors or incumbent medtech groups bring better-funded distribution into the same workflow category.
The exposure is easier to state than the direct competitor list, because the source set is thin on named rivals. Seerlinq does not yet show a publicly documented set of named hospital system customers outside company materials, and the evidence for broader Germany traction remains company-linked rather than independently corroborated [LinkedIn, retrieved 2026] [Life Science Intelligence, December 2025]. That leaves the company vulnerable to better-distributed substitutes, whether from established telemedicine providers that already sit inside provider workflows or from invasive-monitoring incumbents that already have clinical trust in advanced heart-failure management. The company also does not appear, from the public evidence here, to own a dominant patient-acquisition channel; its current wedge seems to depend on physician participation and reimbursement acceptance rather than direct consumer pull [Seerlinq] [EU-Startups, March 2026].
The most plausible 18-month scenario is a split market rather than a clear winner-take-all outcome. Seerlinq is the winner if non-invasive filling-pressure monitoring proves operationally easier for cardiologists to deploy at scale than invasive alternatives, especially in reimbursed public systems where avoiding hospitalization carries clear economic value [Seerlinq] [EU-Startups, March 2026]. Seerlinq is the loser if the category standard remains anchored in incumbent pathways, either because physicians prefer established invasive monitoring in the sickest cohorts or because broader RPM platforms absorb enough of the monitoring budget without requiring a new dedicated device. With no named startup competitor confirmed in the source set, the more conservative read is that Seerlinq's real contest over the next 18 months is against clinical inertia and channel control, not just another startup with a similar deck.
One source, partially checked -- Product positioning and regulatory status are supported by EU-Startups, JACC, and PubMed, but the source set does not confirm named direct competitors or independently verify broader commercial traction claims.
Opportunity
Upside Case
PUBLIC The prize here is not a niche telemonitoring vendor, but a clinically trusted monitoring layer for heart-failure management that can sit between the home and the cardiology clinic in reimbursed care pathways across Europe, and potentially beyond if regulatory and reimbursement milestones continue to fall into place [EU-Startups, March 2026] [Seerlinq, Unknown] [Life Science Intelligence, December 2025].
The headline opportunity is straightforward. If Seerlinq can make non-invasive cardiac filling pressure measurement reliable enough for routine clinical use at home, it could become one of the few heart-failure platforms that changes treatment before decompensation leads to admission, without requiring an implant [EU-Startups, March 2026] [JACC: Basic to Translational Science, January 2025] [PubMed]. That matters because the current public evidence suggests the company is not selling a general wellness app, but a Class IIb medical device system under EU MDR 2017/745, delivered through a nationwide telemedicine programme in Slovakia and framed around an actionable clinical signal rather than generic symptom tracking [EU-Startups, March 2026] [PatientGuard]. The difference is important. Category value in medtech tends to accrue to products that fit regulated workflows, reimbursement rails, and physician decision-making, and Seerlinq has at least early public markers on each of those dimensions, even if commercial scale remains modest and mostly company-reported [Seerlinq, November 2026] [LinkedIn, retrieved 2026].
A plausible route to very large scale is less about direct-to-consumer adoption and more about becoming embedded infrastructure for heart-failure follow-up. The company says its service is fully covered by health insurance in Slovakia, without patient co-payment, and its LinkedIn materials describe reimbursement in Germany as well, though the Germany point remains company-asserted and should be treated cautiously [Seerlinq, Unknown] [LinkedIn, retrieved 2026]. If that model holds, Seerlinq can sell into a budget already earmarked for managing a costly chronic condition, which is a materially stronger starting point than asking providers or patients to create a new spend category.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| National standard in Slovakia | Seerlinq becomes the default remote-monitoring pathway for a meaningful share of heart-failure follow-up in Slovakia, with specialist oversight and insurer-backed deployment | Broader physician adoption within the existing nationwide programme | Public sources already describe a nationwide telemedicine programme in Slovakia, more than 200 participating patients, and over 50 physicians as of November 2026, albeit the latter two are company-reported deployment figures [EU-Startups, March 2026] [Seerlinq, November 2026] |
| Reimbursed expansion into DACH | The company extends from Slovakia into Germany and nearby European markets where MDR certification and payer logic can support a similar care model | Proof of reimbursement and local clinical partnerships in Germany | Seerlinq publicly claims expansion into Germany, and its HeartCore system is described as a certified Class IIb medical device under EU MDR 2017/745, which gives it a regulatory base more portable across the EU than a country-specific digital pilot would have [Life Science Intelligence, December 2025] [EU-Startups, March 2026] |
| Non-invasive alternative to implant monitoring | Seerlinq wins a position as the lower-friction monitoring option for patients and clinicians who want hemodynamic insight without an implanted device | Clinical validation showing useful differentiation between normal and elevated filling pressures in home use | JACC: Basic to Translational Science describes the Seerlinq measurement protocol and algorithmic analysis of PPG signal changes to distinguish normal from elevated filling pressures, while Timspark framed the approach as replacing implants in heart-failure care [JACC: Basic to Translational Science, January 2025] [Timspark, April 2026] |
The compounding mechanism, if it works, is clinical and distributional at the same time. Each additional physician on the platform can bring recurring patient cohorts into a reimbursed monitoring workflow, which in turn should generate more labeled real-world PPG and outcome data, more operational familiarity for care teams, and potentially better algorithm performance over time, though any claim of performance improvement beyond the published descriptions would still be an inference [Seerlinq, November 2026] [JACC: Basic to Translational Science, January 2025]. In practical terms, a platform that already asks patients to use a smartphone app, a blood-pressure monitor, and a proprietary device at home has several surfaces where adherence, workflow, and model tuning can improve together rather than separately [Seerlinq, Unknown] [EU-Startups, March 2026]. The early signs of that loop are visible, if faint: nationwide programme language, physician participation, and active hiring across AI, data science, backend, sales, and clinical research all point to a company trying to deepen both product capability and go-to-market capacity at once [EU-Startups, March 2026] [Seerlinq] [Seerlinq, November 2026].
The size of the win depends on which scenario clears. There is not enough source-grounded market sizing here to support a precise valuation framework, so the cleaner way to frame upside is by category position. If Seerlinq becomes a reimbursed, multi-country monitoring standard for heart failure in Europe, with clinically differentiated non-invasive measurement rather than generic RPM, the outcome could plausibly resemble a strategic medtech asset rather than a local services business (scenario, not a forecast) [EU-Startups, March 2026] [Life Science Intelligence, December 2025]. The evidence base does not justify attaching a hard enterprise value number in public, but it does support the core upside logic: a regulated Class IIb product, tied to a high-cost chronic condition, already operating in live care pathways, can create disproportionate value if it proves it reduces admissions and travels across reimbursement systems [EU-Startups, March 2026] [PatientGuard] [Seerlinq, Unknown].
One source, partially checked -- This section relies on one independent named-publisher source for regulatory and programme claims, one academic source for measurement methodology, and several company-reported deployment and reimbursement claims that remain only partially corroborated [EU-Startups, March 2026] [JACC: Basic to Translational Science, January 2025] [Seerlinq, November 2026] [Seerlinq, Unknown].
Sources
Publicly reported
[Seerlinq, November 2026] Viac než 200 pacientov a 50 lekárov: Program Seerlinq rastie! | https://seerlinq.com/novinky/viac-nez-200-pacientov-50-lekarov-program-seerlinq-rastie
[VCBacked, July 2023] Seerlinq - Funding, Valuation, Investors, News | https://o.parsers.vc/startup/seerlinq.com/
[EU-Startups, March 2026] Seerlinq HeartCore system is a certified Class IIb medical device under EU MDR 2017/745 | https://www.eu-startups.com/
[JACC: Basic to Translational Science, January 2025] Seerlinq algorithm analyzes changes in PPG signals to differentiate between normal and elevated filling pressures | https://www.jacc.org/
[Healthcare.digital] Allan Böhm is a co-founder of Seerlinq | https://healthcare.digital/
[LinkedIn, retrieved 2026] Allan Böhm - Seerlinq | LinkedIn | https://sk.linkedin.com/in/allan-b%C3%B6hm-42b75b66
[CB Insights] Seerlinq - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/seerlinq
[Crunchbase] Seerlinq - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/seerlinq
[Seerlinq] Seerlinq | https://seerlinq.com/
[Commonwealth Fund] International Health Care System Profiles: Germany | https://www.commonwealthfund.org/
[PatientGuard] What is a Class IIb medical device? | https://patientguard.com/
[Timspark, April 2026] How Seerlinq Is Replacing Implants In Heart Failure Care | https://timspark.com/
[PubMed] Developed a non-invasive method to assess left ventricular filling pressures by analysing the photoplethysmography signal with Seerlinq HeartCore technology | https://pubmed.ncbi.nlm.nih.gov/
[Life Science Intelligence, December 2025] Allan Böhm, Seerlinq s.r.o. - LSI Europe ’25 | https://lifesciencemarketresearch.com/videos/allan-bohm-seerlinq-s-r-o-lsi-europe-25/
[NextStep Science Podcast] Allan Böhm: Budúcnosť medicíny je personalizovaná - časť 1. | NextStep Science Podcast | https://nextstepscience.podbean.com/e/allan-bohm-buducnost-mediciny-je-personalizovana-cast-1/
[Seerlinq, Unknown] About us | https://seerlinq.com/en/about-us
Articles about Seerlinq
- Seerlinq's AI Device Spots Heart Failure Before the Hospital — The Slovak startup's certified system uses a smartphone and PPG signals to detect early deterioration, with reimbursement secured in Slovakia and Germany.